TCIM
CRVS icon

TIAA CREF Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

TIAA CREF Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$88K Sell
21,909
-4
-0% -$17 ﹤0.01% 2970
2018
Q4 		$80K Sell
21,913
-732
-3% -$4.99K ﹤0.01% 2977
2018
Q3 		$194K Sell
22,645
-5,279
-19% -$52.8K ﹤0.01% 2987
2018
Q2 		$307K Buy
27,924
+4,649
+20% +$51.9K ﹤0.01% 2937
2018
Q1 		$268K Hold
23,275
– – ﹤0.01% 2929
2017
Q4 		$241K Sell
23,275
-673
-3% -$8.62K ﹤0.01% 2984
2017
Q3 		$382K Buy
23,948
+594
+3% +$8.22K ﹤0.01% 2939
2017
Q2 		$283K Buy
23,354
+16,173
+225% +$173K ﹤0.01% 3046
2017
Q1 		$149K Buy
7,181
+2,170
+43% +$34K ﹤0.01% 3024
2016
Q4 		$72K Buy
5,011
+428
+9% +$6.51K ﹤0.01% 3096
2016
Q3 		$75 Sell
4,583
-12,778
-74% -$184K ﹤0.01% 3094
2016
Q2 		$248K Buy
+17,361
New +$235K ﹤0.01% 3063

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TIAA CREF Investment Management's CRVS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Corvus Pharmaceuticals (CRVS) stake by 0.02% in Q1 2019, selling an estimated $17 and leaving 21,909 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #2970.

TIAA CREF Investment Management first reported a position in CRVS in Q2 2016 and has held it in 12 quarters since. The position peaked at $382K in Q3 2017. 58 funds tracked by Wall St. Rank hold CRVS as of Q1 2019.

  • TIAA CREF Investment Management held 21,909 shares of Corvus Pharmaceuticals worth $88K as of Q1 2019.
  • TIAA CREF Investment Management sold 4 Corvus Pharmaceuticals shares in Q1 2019, an estimated $17.
  • Corvus Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2970 holding.
  • TIAA CREF Investment Management first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 12 quarters since.
  • TIAA CREF Investment Management's Corvus Pharmaceuticals position peaked at $382K in Q3 2017.
  • 58 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.